Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
NCT03004924 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SHP640
- DRUG PVP-I 0.6%
Study Locations (20)
California
- Milton M. Hom, OD, FAAO — Azusa
- Clark S Tsai Eye Center — Concord
- Lugene Eye Institute Inc — Glendale
- Mark B. Kislinger, MD, Inc. — Glendora
- Inland Eye Specialists — Hemet
- Lakeside Vision Center — Irvine
- Hull Eye Center — Lancaster
- Eye Physicians of Long Beach — Long Beach
- Oxford Optical — Los Angeles
- Sok H. Nam, M.D. Inc. — Los Angeles
- University of Southern California — Los Angeles
- Macy Eye Center — Los Angeles
- North Valley Eye Medical Group Inc — Mission Hills
- North Bay Eye Associates, Inc. — Petaluma
- Arch Health Partners — Poway
Arizona
- Arizona Eye Center — Chandler
- Cornea and Cataract Consultants of Arizona — Phoenix
- M&M Eye Institute — Prescott
- Schwartz Laser Eye Center — Scottsdale
- Walman Eye Center — Sun City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 753 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2018-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004924
The ClinicalTrials.gov registry entry for NCT03004924 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 753 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 56 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03004924 reports 20 study locations spanning 2 distinct geographic areas — top geographies include California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03004924 about?
NCT03004924 is a clinical study titled "Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo". The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.
What is the current status of trial NCT03004924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 753 participants. The study started on 2017-03-29. Estimated completion is 2018-10-01.
What conditions does trial NCT03004924 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03004924?
The interventions under investigation include: Placebo (DRUG), SHP640 (DRUG), PVP-I 0.6% (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03004924?
This trial is sponsored by Shire, which has 56 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03004924 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.